Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia
- PMID: 22825369
- PMCID: PMC3616136
- DOI: 10.1001/archneurol.2012.1608
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia
Abstract
Objective: To determine the relative contributions of individual pathologic protein deposits associated with dementia in patients with Parkinson disease (PD).
Design: Autopsied patients were analyzed from February 24, 2005, through July 25, 2010, to determine the distribution and severity of individual pathologic protein deposits (α-synuclein, Aβ, and tau) using routine protocols for histologic and immunohistochemical analysis and established neuropathologic staging criteria. Clinical data were extracted from an electronic medical record system used for all patients with PD.
Patients: Thirty-two consecutive autopsied patients treated at the Washington University Movement Disorders Center who had neuropathologic confirmation of PD and a history of dementia, regardless of the timing of the onset of dementia with respect to motor symptoms.
Results: Three pathologic subgroups of dementia associated with PD were identified: (1) predominant synucleinopathy (Braak Lewy body stages 5-6) (12 [38%]), (2) predominant synucleinopathy with Aβ deposition (Braak amyloid stages B-C) but minimal or no cortical tau deposition (19 [59%]), and (3) synucleinopathy and Aβ deposition with at least moderate neocortical tauopathy (Braak tau stages 5-6; 1 [3%]). Kaplan-Meier and Cox regression analyses revealed that patients with synucleinopathy plus Aβ deposition had significantly shorter survival (years from PD onset until death and years from dementia onset until death) than patients with synucleinopathy only.
Conclusions: Dementia associated with PD has 2 major pathologic subgroups: neocortical synucleinopathy and neocortical synucleinopathy with Aβ deposition. Alzheimer disease with neocortical Aβ and tau deposition does not commonly cause dementia with PD. Furthermore, accumulation of Aβ is associated with lower survival rates in PD patients with dementia. Additional studies are needed to prospectively determine the association between α-synuclein and Aβ accumulation and the role of Aβ in the development and progression of cognitive impairment in PD.
Figures

References
-
- Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844. - PubMed
-
- Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67(11):1931–1934. - PubMed
-
- Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318 (1):121–134. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- NS058714/NS/NINDS NIH HHS/United States
- R01 NS075321/NS/NINDS NIH HHS/United States
- R01 NS041509/NS/NINDS NIH HHS/United States
- NS41509/NS/NINDS NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- NS48924/NS/NINDS NIH HHS/United States
- KL2 RR024994/RR/NCRR NIH HHS/United States
- R01 NS058714/NS/NINDS NIH HHS/United States
- RF1 NS075321/NS/NINDS NIH HHS/United States
- KL2 TR000450/TR/NCATS NIH HHS/United States
- K23 NS081087/NS/NINDS NIH HHS/United States
- P30 NS057105/NS/NINDS NIH HHS/United States
- P50 AG05681/AG/NIA NIH HHS/United States
- K08 NS048924/NS/NINDS NIH HHS/United States
- NS075321/NS/NINDS NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P01 AG03991/AG/NIA NIH HHS/United States
- UL1RR024992/RR/NCRR NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical